Bacterial Lysates As Immunotherapies for Respiratory Infections: Methods of Preparation

Overview

Journal Front Bioeng Biotechnol

Date 2020 Jun 26

PMID 32582669

Citations 16

Authors

Norma Suarez

Florencia Ferrara

Analia Rial

Valerie Dee

Jose A Chabalgoity

Affiliations

Soon will be listed here.

Abstract

Bacterial lysates, prepared from the microorganisms most frequently involved in human Respiratory Tract Infections (RTIs) have been in the market for several decades, and at present, several different brands are available in many countries worldwide. They all claimed to exert local and systemic immunomodulatory effects but different clinical trials show disparate results between them. The lack of consistency of predicted therapeutic effects has undermined their clinical use and hampered licensing in several countries. One explanation for such lack of consistency in the results is that their methods of preparation are also very different. Here, we review the available literature describing methods of preparation of bacterial lysates, including patent disclosure documents. We found a great variety of methodologies of preparation and a lack of standardized procedures among them. The main conclusion of our study is that there is a clear need for standardized protocols of production to obtain comparable results in clinical trials worldwide.

Citing Articles

Deciphering the oncogenic influence of : Implications of matrix metalloproteinase activation.

Nambiar J, Venugopal M, Shaji S, Bose C, Rajeev A, Kalliadan S Heliyon. 2025; 11(4):e42538.

PMID: 40028520 PMC: 11870157. DOI: 10.1016/j.heliyon.2025.e42538.

Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection?.

Di Gioacchino M, Santilli F, Pession A Biomolecules. 2024; 14(10).

PMID: 39456182 PMC: 11505618. DOI: 10.3390/biom14101249.

UNAM-HIMFG Bacterial Lysate Activates the Immune Response and Inhibits Colonization of Bladder of Balb/c Mice Infected with the Uropathogenic CFT073 Strain.

Acevedo-Monroy S, Hernandez-Chinas U, Rocha-Ramirez L, Medina-Contreras O, Lopez-Diaz O, Ahumada-Cota R Int J Mol Sci. 2024; 25(18).

PMID: 39337365 PMC: 11432767. DOI: 10.3390/ijms25189876.

Gut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders.

Verma A, Inslicht S, Bhargava A Cells. 2024; 13(17.

PMID: 39273008 PMC: 11394554. DOI: 10.3390/cells13171436.

The Role of Postbiotics in Asthma Treatment.

Wegrzyn K, Jasinska A, Janeczek K, Feleszko W Microorganisms. 2024; 12(8).

PMID: 39203484 PMC: 11356534. DOI: 10.3390/microorganisms12081642.

References

Capetti A, Cossu M, Carenzi L, Rizzardini G . Four years of immunization with OM-85 BV to prevent respiratory infections in HIV+ patients. Hum Vaccin Immunother. 2013; 9(9):1849-51. PMC: 3906347. DOI: 10.4161/hv.25104. View

Thomas D, Weiss E . Response of mice to injection of ribosomal fraction from group B Neisseria meningitidis. Infect Immun. 1972; 6(3):355-63. PMC: 422541. DOI: 10.1128/iai.6.3.355-363.1972. View

Braido F, Melioli G, Candoli P, Cavalot A, Di Gioacchino M, Ferrero V . The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial. Immunol Lett. 2014; 162(2 Pt B):185-93. PMC: 7173099. DOI: 10.1016/j.imlet.2014.10.026. View

Caliot E, Libon C, Kerneis S, Pringault E . Translocation of ribosomal immunostimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand J Immunol. 2000; 52(6):588-94. DOI: 10.1046/j.1365-3083.2000.00819.x. View

Del-Rio-Navarro B, Espinosa Rosales F, Flenady V, Sienra-Monge J . Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006; (4):CD004974. DOI: 10.1002/14651858.CD004974.pub2. View

Esposito S, Bianchini S, Polinori I, Principi N . Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study. Int J Environ Res Public Health. 2019; 16(6). PMC: 6466214. DOI: 10.3390/ijerph16061065. View

YOUMANS A, YOUMANS G . IMMUNOGENIC ACTIVITY OF A RIBOSOMAL FRACTION OBTAINED FROM MYCOBACTERIUM TUBERCULOSIS. J Bacteriol. 1965; 89:1291-8. PMC: 277642. DOI: 10.1128/jb.89.5.1291-1298.1965. View

Aziminia N, Hadjipavlou M, Philippou Y, Pandian S, Malde S, Hammadeh M . Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2018; 123(5):753-768. DOI: 10.1111/bju.14606. View

Michel F, Dussourd DHinterland L, Bousquet J, Pinel A, Normier G . Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans. Infect Immun. 1978; 20(3):760-9. PMC: 421924. DOI: 10.1128/iai.20.3.760-769.1978. View

10.

Coviello S, Wimmenauer V, Polack F, Irusta P . Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4. Hum Vaccin Immunother. 2014; 10(10):2896-902. PMC: 5443103. DOI: 10.4161/hv.29784. View

11.

Braido F, Melioli G, Cazzola M, Fabbri L, Blasi F, Moretta L . Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre,.... Pulm Pharmacol Ther. 2015; 33:75-80. DOI: 10.1016/j.pupt.2015.03.006. View

12.

Huber M, Krauter K, Winkelmann G, Bauer H, Rahlfs V, Lauener P . Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol. 2001; 22(12):1103-11. DOI: 10.1016/s0192-0561(00)00070-9. View

13.

Cazzola M, Anapurapu S, Page C . Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2011; 25(1):62-8. DOI: 10.1016/j.pupt.2011.11.002. View

14.

Rozy A, Chorostowska-Wynimko J . Bacterial immunostimulants--mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol. 2008; 76(5):353-9. View

15.

Thompson H, Snyder I . Protection against pneumococcal infection by a ribosomal preparation. Infect Immun. 1971; 3(1):16-23. PMC: 416101. DOI: 10.1128/iai.3.1.16-23.1971. View

16.

Pan L, Jiang X, Guo J, Tian Y, Liu C . Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. J Clin Pharmacol. 2015; 55(10):1086-92. DOI: 10.1002/jcph.518. View

17.

Bousquet J, Fiocchi A . Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review. Paediatr Drugs. 2006; 8(4):235-43. DOI: 10.2165/00148581-200608040-00003. View

18.

Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica G . Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis. 2008; 2(3):335-45. PMC: 2695191. View

19.

Wenger M, Dephillips P, Bracewell D . A microscale yeast cell disruption technique for integrated process development strategies. Biotechnol Prog. 2008; 24(3):606-14. DOI: 10.1021/bp070359s. View

20.

Zagolski O, Strek P, Kasprowicz A, Bialecka A . Effectiveness of Polyvalent Bacterial Lysate and Autovaccines Against Upper Respiratory Tract Bacterial Colonization by Potential Pathogens: A Randomized Study. Med Sci Monit. 2015; 21:2997-3002. PMC: 4599189. DOI: 10.12659/MSM.893779. View